The multidrug ABC transporter BmrC/BmrD of Bacillus subtilis is regulated via a ribosome-mediated transcriptional attenuation mechanism by Reilman, Ewoud et al.
  
 University of Groningen
The multidrug ABC transporter BmrC/BmrD of Bacillus subtilis is regulated via a ribosome-
mediated transcriptional attenuation mechanism





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2014
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Reilman, E., Mars, R. A. T., van Dijl, J. M., & Denham, E. L. (2014). The multidrug ABC transporter
BmrC/BmrD of Bacillus subtilis is regulated via a ribosome-mediated transcriptional attenuation
mechanism. Nucleic Acids Research, 42(18), 11393-11407. https://doi.org/10.1093/nar/gku832
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Published online 12 September 2014 Nucleic Acids Research, 2014, Vol. 42, No. 18 11393–11407
doi: 10.1093/nar/gku832
The multidrug ABC transporter BmrC/BmrD of
Bacillus subtilis is regulated via a ribosome-mediated
transcriptional attenuation mechanism
Ewoud Reilman, Ruben A. T. Mars, Jan Maarten van Dijl* and Emma L. Denham
Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1,
P.O. box 30001, 9700 RB Groningen, the Netherlands
Received November 23, 2013; Revised August 12, 2014; Accepted September 1, 2014
ABSTRACT
Expression of particular drug transporters in re-
sponse to antibiotic pressure is a critical element
in the development of bacterial multidrug resistance,
and represents a serious concern for human health.
To obtain a better understanding of underlying regu-
latory mechanisms, we have dissected the transcrip-
tional activation of the ATP-binding cassette (ABC)
transporter BmrC/BmrD of the Gram-positive model
bacterium Bacillus subtilis. By using promoter-GFP
fusions and live cell array technology, we demon-
strate a temporally controlled transcriptional activa-
tion of the bmrCD genes in response to antibiotics
that target protein synthesis. Intriguingly, bmrCD ex-
pression only occurs during the late-exponential and
stationary growth stages, irrespective of the timing
of the antibiotic challenge. We show that this is due
to tight transcriptional control by the transition state
regulator AbrB. Moreover, our results show that the
bmrCD genes are co-transcribed with bmrB (yheJ),
a small open reading frame immediately upstream of
bmrC that harbors three alternative stem-loop struc-
tures. These stem-loops are apparently crucial for
antibiotic-induced bmrCD transcription. Importantly,
the antibiotic-induced bmrCD expression requires
translation of bmrB, which implies that BmrB serves
as a regulatory leader peptide. Altogether, we demon-
strate for the first time that a ribosome-mediated tran-
scriptional attenuation mechanism can control the
expression of a multidrug ABC transporter.
INTRODUCTION
Since the clinical introduction of antibiotics, bacteria have
evolved efficient mechanisms to counteract their effects.
This has resulted in the emergence of multidrug resistant
(MDR) bacterial pathogens, which is a serious threat to
public health as the treatment of infections caused by these
pathogens is becoming increasingly difficult (1). An effec-
tive strategy for bacteria to achieve resistance to a multi-
tude of antibiotics is the expression of efflux pumps, such as
ATP-binding cassette (ABC) transporters, that can actively
excrete harmful substances from the cell (1,2).
The model bacterium Bacillus subtilis, a close relative of
notoriously drug-resistant Gram-positive bacteria, such as
Staphylococcus aureus, is equipped with an extensive reper-
toire of genes that encode for potential drug efflux trans-
porters (3). These include a significant number of ABC
transporters (4). Eight of the 78ABC transport systems that
are encoded by the genome ofB. subtilis have been classified
as potential MDR-like transporters (4). Among these eight
is the heterodimeric ABC transporter YheI/YheH, which
was renamed BmrC/BmrD (in short BmrCD) due to its ho-
mology to the LmrC/LmrD ABC transporter of Lactococ-
cus lactis (5).
BmrCD was the first multidrug ABC transporter in B.
subtilis that was shown to function as a heterodimer. Tor-
res et al. (6) used inside-out membrane vesicles to demon-
strate that BmrCD can mediate efflux of several fluo-
rescent substrates of MDR-ABC transporters, including
Hoechst 33342, doxorubicin and mitoxantrone. In addi-
tion, they investigated the transcriptional response of B.
subtilis to subinhibitory concentrations of 46 different an-
tibiotics. Eleven of these antibiotics, most of which act as
inhibitors of protein synthesis, were shown to significantly
increase the transcription of the bmrCD operon (6). These
included ribosome-targeted antibiotics, such as chloram-
phenicol, erythromycin and gentamycin, which was consis-
tent with an earlier study on antibiotic-induced gene expres-
sion in B. subtilis (7).
In the present study, we have dissected the transcriptional
regulation of the bmrCD genes in response to ribosome-
targeted antibiotics to obtain a better understanding of the
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underlying regulatory mechanisms. The results show that
induction of bmrCD is controlled at two levels. First, this
process is tightly restricted to the transition and stationary
growth phases by the main transition state regulator AbrB.
Second, we show that antibiotic-induced expression of bm-
rCD is regulated via a dedicated ribosome-mediated tran-
scriptional attenuation mechanism that requires the yheJ-
encoded leader peptide. In view of the location of yheJ im-
mediately upstream of bmrC, and the intimate relationship
between yheJ translation and the expression of bmrCD, we
have renamed yheJ to bmrB.
MATERIALS AND METHODS
Plasmids, bacterial strains and growth condition
The plasmids and bacterial strains used in this study are
listed in Supplementary Table S1, and the primers used for
plasmid constructions in Supplementary Table S2. B. sub-
tilis 168 and Escherichia coli TG1 were grown with vigor-
ous agitation in Lysogeny broth (LB; Difco laboratories)
at 37◦C. Where appropriate, the growth medium was sup-
plemented with antibiotics: ampicillin 100 g/ml, spectino-
mycin 100 g/ml, chloramphenicol 5 g/ml (B. subtilis) or
10 g/ml (E. coli).
Construction of chromosomally integrated transcriptional 5′-
gfp fusions
Transcriptional green fluorescent protein (GFP) fusions
were constructed using the integrative pBaSysBioII plas-
mid, as described previously (8). The 5′ upstream regions
of bmrB or bmrC were amplified by polymerase chain re-
action (PCR) with the Phusion Hot Start High-Fidelity
DNA Polymerase (Finnzymes, NEB), and then joined with
the pBaSysBioII plasmid by Ligation-Independent Cloning
(LIC). The resulting plasmids were used to transform B.
subtilis 168 as described by Kunst and Rapoport (9). Since
pBaSysBioII cannot replicate in B. subtilis, its derivatives
carrying the cloned 5′ upstream regions of bmrB or bmrC
integrated at the respective loci via single cross-over recom-
bination. This placed the respective gfp fusion in single copy
on the chromosome at the original locus and, at the same
time the sequence cloned in pBaSysBioII was duplicated
(for details see 8). For each transcriptional-GFP fusion,
three independent clones were selected and used for further
experiments. In addition, genomic DNA isolated from one
of these clones was used as a template to PCR-amplify the
complete or a truncated version of the respective transcrip-
tional GFP fusion. The resulting PCR-amplified fragments
were cloned into pRMC, a LIC-adapted derivative of the
pXTC plasmid (10) that allows the incorporation of genes
via double cross-over recombination into the chromosomal
amyE gene. Importantly, the xylose-inducible promoter of
pXTCwas removed from pRMC,making this plasmid suit-
able for driving GFP expression exclusively from inserted
promoter and regulatory sequences. Integration of the dif-
ferent transcriptional GFP fusions into the amyE locus was
confirmed by growing transformants on starch-containing
plates and testing the absence of -amylase secretion by
staining of the plates with iodine as described previously
(10).
Construction of plasmid-borne transcriptional bmrB-gfp fu-
sions
Plasmid pRM3 was constructed by combining the back-
bone of plasmid pHB201 (11) with the xylose-inducible
promoter from pXTC (10) using circular polymerase ex-
tension cloning and primers listed in Supplementary Ta-
ble S2 (12). In this manner, the AscI LIC site was intro-
duced into pRM3 by primer overlap. Two different frag-
ments of bmrB including the 5′ untranslated region (UTR)
and coding sequence, either with or without the terminator
region, were amplified by PCR. The resulting DNA frag-
ments were fused by overlap-PCR with gfpmut3, includ-
ing an optimal ribosome-binding site (RBS) (8). The re-
sulting overlapped PCR products were gel-extracted and
cloned into plasmid pRM3 via LIC (13) resulting in plas-
mids pRM3-bmrB162 and pRM3-bmrB109. Mutations in
pRM3-bmrBTerm were introduced by site-directed muta-
genesis using the bmrB-gfp fusion of pRM3-bmrB162 as a
template. For this purpose, bmrB-gfpwas amplified by PCR
in two separate fragments, one of which included the re-
quired mutations. Subsequently, these PCR fragments were
joined by overlap-PCR, gel-extracted and cloned into plas-
mid pRM3 via LIC. The sequences required for pRM3-
bmrBstart and pRM3-bmrB−CodonOpt, were commer-
cially synthesized by Integrated DNA Technologies (http:
//eu.idtdna.com/). PCR fragments of these synthesized se-
quences, consisting of the front part of bmrB, were fused to
the terminator region and GFP by overlap-PCR.
Live cell array (LCA) analyses
LCA analyses with B. subtilis were performed as described
previously (8,14,15). All strains used for LCA analysis were
grown overnight in LB, diluted 1000-fold and grown in 100
l cultures in 96-well flat bottom microtiter plates (Greiner
Bio-One). Cultures were grown for 14 h in a Biotek syn-
ergy 2 plate reader, monitoring both growth by optical
density readings at 600 nm (OD600nm) and GFP fluores-
cence (excitation 485/20 nm, emission 528/20 nm) at 5-
or 10-min intervals. The promoter-GFP strains were either
exposed to subinhibitory concentrations of antibiotics or
mock-treated during early exponential growth (OD600 nm
corrected for 1 cm path length = ∼0.5). Background flu-
orescence from the isogenic wild-type control strain not ex-
pressing GFP was subtracted. Arbitrary transcriptional ac-
tivity units (TAU) represent the increase in GFP expression
levels during each 5- or 10-min interval and were calculated
using the equation: (GFPt − GFPt−1)/OD600t (where t rep-
resents a given time point at which fluorescence was mea-
sured, and t − 1 the preceding time point at which fluo-
rescence was measured). Expression of the transcriptional-
GFP fusions on pRM3 was induced in exponentially grow-
ing cells (OD600 nm ∼0.18) by the addition of xylose (0.1%
final concentration) either with or without supplementa-
tion of lincomycin (0.75 g/ml). For the experiments with
strains containing pRM3-borne gfp fusions, the final GFP
activity levels were corrected by subtracting the GFP activ-
ity levels measured for non-induced cultures. The xylose-
induced GFP activity levels thus obtained were expressed
in arbitrary units (AU). Data depicted in the LCA figures
were derived from one of three representative experiments.
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RNA extraction, reverse transcription and real-time PCR
B. subtilis 168 was inoculated from an overnight culture
into 150 ml LB medium to an OD600 of 0.05. During ex-
ponential growth (OD600 ∼0.6) the cells were either mock-
treated or exposed to lincomycin (0.5 g/ml) for 150 min.
Next, total RNAwas extracted according to themethod de-
scribed by Eymann et al. (16). The RNA was reverse tran-
scribed into cDNA using Taqman RT-PCR reagents (Ap-
plied Biosystems, LifeTechnologies) according to themanu-
facturer’s protocol. The resulting cDNAwas used as a PCR
template to confirm the structure of the bmrB/bmrC/bmrD
operon (in short bmrBCD) with Taq polymerase (Life Tech-
nologies) and the quantitative PCR (qPCR) primers bmrB-
foward and bmrC-reverse (Supplementary Table S2). Real-
time qPCR (GoTaq qPCR Master Mix, Promega) was
performed according to the manufacturer’s protocol using
an Applied Biosystems 7500 Real-time PCR system and
the primer sets specified in Supplementary Table S2. The
recF and ssrA genes were included as reference genes. Data
analysis was carried out using the accompanying Applied
Biosystems software package (v.2.0.5).
RESULTS
Transition phase-dependent induction of bmrCD by
ribosome-targeted antibiotics
The BmrCD ABC transporter was previously shown to be
regulated by exposure to several ribosome-targeted antibi-
otics (6,7). To gain further insights into the mechanisms in-
volved in this regulation, the genomic environment of the
bmrCD genes was carefully mapped using data from a re-
cent high-resolution transcriptional analysis of B. subtilis
grown under 104 different conditions (17). Based on these
data, which are schematically represented in Supplementary
Figure S1A, we postulated that the bmrC and bmrD genes
are co-transcribed with bmrB (previously known as yheJ),
a small and as yet uncharacterized gene of 162 bp that ends
119 bp upstream from the start codon of bmrC (Figure 1A
and B). This view was confirmed by a reverse transcription
PCR analysis (Supplementary Figure S1B). It thus seems
that the bmrBCD operon is transcribed from a conjoint pro-
moter which, according to the B. subtilis Expression Data
Browser (http://genome.jouy.inra.fr/seb), is located ∼70 bp
upstream of bmrB (Figure 1B).
To gain further insight into the mechanisms involved in
bmrCD expression, we transcriptionally fused the 600-bp
region upstream from the −18 position of bmrC to gfp and
integrated one copy of this fusion by single cross-over re-
combination into the native bmrC locus of the B. subtilis
chromosome (Figure 1A). The resulting strain 168 BSBII-
5′bmrC-gfpwas then used tomonitor the antibiotic-induced
expression of bmrCD in ‘real-time’ following the LCA ap-
proach as detailed in the Materials and Methods. To deter-
mine the baseline gfp expression in B. subtilis 168 BSBII-
5′bmrC-gfp, this strain was cultured in LB without antibi-
otics. As shown in Figure 2A, relatively little transcriptional
activity (∼500 TAU) was detectable during exponential
growth, but the activity increased during the late transition
and early stationary growth phases to ∼1950 TAU. Next,
exponentially growing cells (OD600nm ∼0.5) carrying the
5′bmrC-gfp fusion were exposed to subinhibitory concen-
trations of the ribosome-targeted antibiotics chlorampheni-
col (0.2g/ml), erythromycin (0.02g/ml), lincomycin (0.2
g/ml), kanamycin (0.2g/ml) or gentamycin (0.2g/ml).
The addition of chloramphenicol or erythromycin resulted
in a slight reduction in the growth rate and a slight drop in
the maximum OD600 nm that was reached (Figure 2A). Fol-
lowing addition of either of these two antibiotics, the tran-
scriptional activity of the 5′bmrC-gfp fusion remained un-
altered at baseline levels for ∼75 min and then increased
during a period of ∼50–200 min to a maximum (∼4350–
5900 TAU, respectively) after which it gradually returned
to baseline levels. Interestingly, while the presence of 0.2
g/ml lincomycin had no inhibitory effect on growth, it
triggered the strongest induction of the 5′bmrC-gfp fusion
(Figure 2A). After a ∼75-min delay, lincomycin induced
the transcriptional activity of the 5′bmrC-gfp fusion to a
maximum of ∼11 800 TAU and this level was sustained
for ∼90 min before returning to baseline. In contrast, the
antibiotics kanamycin and gentamycin did not induce the
5′bmrC-gfp fusion. The latter observation was unexpected
as earlier studies had suggested that gentamycin would in-
duce bmrCD expression (6), a finding that we were unable
to reproduce. In fact, the gfp transcription even seemed to
decrease in response to these antibiotics. In this respect it
is noteworthy that the latter two antibiotics target the 30S
ribosomal subunit, while the bmrCD-activating antibiotics
chloramphenicol, erythromycin and lincomycin are specific
for the 50S subunit.
We subsequently verified the dose-dependence of the re-
sponse to the most potent inducer of bmrCD transcription,
lincomycin, by subjecting B. subtilis 168 BSBII-5′bmrC-gfp
to increasing concentrations of lincomycin. This showed
that the transcriptional response toward lincomycin was in-
deed dose-dependent (Figure 2B). The lowest concentration
of lincomycin, (0.02 g/ml) induced the 5′bmrC-gfp fusion
to a maximum of∼5800 TAU. By increasing the lincomycin
concentration 10-fold (0.2 g/ml), the transcriptional ac-
tivity was doubled, and a further 10-fold increase (2 g/ml)
induced the bmrC promoter activity to ∼17 800 TAU. This
relatively high concentration of lincomycin slightly affected
growth of the 168 BSBII-5′bmrC-gfp strain (Figure 2B).
Intriguingly, the transcription of bmrCD was highly
growth phase-dependent as evidenced by the ∼75-min de-
lay between the administration of chloramphenicol, ery-
thromycin or lincomycin and the induction of promoter ac-
tivity. Specifically, this delayed promoter activation coin-
cided with the late transition stage in growth. To further
investigate the apparent growth phase-dependent transcrip-
tional activation of bmrCD, lincomycin (0.02 g/ml) was
administered to the culture at the start of the experiment
(T0; Figure 2C). Also in this case, the 5′bmrC-gfp fusion
remained largely silent until the ∼300 min time point af-
ter which its activity increased to a peak of ∼9100 TAU.
The GFP activity remained constant for ∼200 min before
returning to basal level. Thus, transcriptional activation of
bmrCD followed exactly the same pattern as observed when
the antibiotic was added after 200 min of growth. This
shows that bmrCD expression as reflected by the 5′bmrC-
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Figure 1. Genomic context of the bmrCD locus and transcriptional GFP fusions. A. The top line depicts the genomic context of the ABC transporter
genes bmrC and bmrD, which are preceded by the small open reading frame bmrB. The two lines below represent the relative positions of the two regions
selected for construction of the transcriptional 5′bmrC-gfp and 5′bmrB-gfp fusions. B.Detailed representation of the regulatory region upstream of bmrC,
including the segment of bmrB (nucleotides 60–162) in which predicted terminator, anti-terminator and anti-anti-terminator structures are encoded. These
three putative structures are assigned with their nucleotide positions relative to the first nucleotide of bmrB. The black arrowhead marks nucleotide 109
after which bmrB was truncated in pRM3-bmrB109. In addition, the 5′UTR upstream of bmrB and the intergenic region between bmrB and bmrC are
indicated. C. Structures of the putative anti-anti-terminator, anti-terminator and terminator, with their respective sizes and Gibbs free energy (G) values,
as predicted by RibEx: Riboswitch Explorer. The overlap in the terminator and anti-terminator structures is marked in bold, and the overlap in the
anti-terminator and anti-anti-terminator structures is marked by underlining.
gfp fusion is tightly regulated in a growth-phase-dependent
manner.
To exclude the possibility that the delayed transcriptional
response of the 5′bmrC-gfp fusion was caused by a direct
effect of the antibiotics on GFP expression levels, a strain
with an isopropyl -D-1-thiogalactopyranoside (IPTG)-
inducible transcriptional 5′-GFP fusion, B. subtilis 168 BS-
BII spac-gfp, was included in the experiments (Supplemen-
tary Figure S2). A final concentration of 0.1 mM IPTG
was added to exponentially growing bacteria, which, as ex-
pected, resulted in an immediate and strong induction of
the spac-gfp fusion. Importantly, the addition of lincomycin
(2.0 g/ml) had no detectable effect on the IPTG-induced
GFP production, excluding a direct inhibitory effect of this
antibiotic on the production of active GFP. Taken together,
these observations imply that bmrCD expression is induced
by a subset of ribosome-targeted antibiotics, and that this
induction is limited to the late transition and early station-
ary growth phases.
The bmrBCD promoter determines growth phase-controlled
bmrCD expression
Notably, the 5′bmrC-gfp fusion was constructed to moni-
tor bmrCD transcription and, for this purpose, the 600-bp
region directly upstream of bmrC was cloned into pBaSys-
BioII. As a consequence, transcription of the 5′bmrC-gfp
fusion was not only subject to control by the upstream bm-
rBCD promoter region, but also to possible regulatory se-
quences within bmrB (Figure 1A). To establish whether the
antibiotic-induced and temporally controlled transcription
of bmrCD could be entirely attributed to the bmrBCD pro-
moter, a second pBaSysBioII-based GFP reporter fusion
was constructed using the 600-bp region directly upstream
of bmrB (Figure 1A). One copy of the resulting transcrip-
tional 5′bmrB-gfp fusion was introduced by single cross-
over recombination into the bmrB locus of the B. subtilis
chromosome. Next, the resulting strain BSBII-5′bmrB-gfp
was grown under the same antibiotic stress conditions as
described above. As shown in Figure 3A and B, the 5′bmrB-
gfp fusion displayed a growth phase-dependent expression
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Figure 2. LCA real-time analysis of bmrCD transcription. A. Growth of B. subtilis BSBII-5′bmrC-gfp (OD600 nm; gray line) and bmrC transcriptional
activity (solid black line) in response to the ribosome-targeted antibiotics chloramphenicol, erythromycin, lincomycin, kanamycin or gentamycin. Arrows
indicate the time points at which antibiotics or an equivalent volume of water (‘no antibiotics’) were added. B. Dose-dependent response of 5′bmrC-gfp
transcription to increasing concentrations of lincomycin. Bold lines indicate transcriptional activity and thin lines indicate bacterial growth. The arrow
indicates the time point at which lincomycin was added. C. Transcriptional response of B. subtilis BSBII-5′bmrC-gfp to an early exposure to lincomycin.
The bold line indicates transcriptional activity and the dashed line indicates bacterial growth. Lincomycin (final concentration: 0.02 g/ml) was added at
the start of the culture, as indicated by the arrow. Cultures entered the transition phase between exponential and post-exponential growth at OD600 of ∼1.
profile, similar to the 5′bmrC-gfp fusion. In all tested condi-
tions, the 5′bmrB-gfp fusion was activated during the transi-
tion from exponential to stationary growth (Figure 3A and
B), matching the time point of the antibiotic-induced acti-
vation observed in the BSBII-5′bmrC-gfp strain (Figure 2).
However, the BSBII-5′bmrB-gfp strain did not respond
to the antibiotics chloramphenicol, erythromycin and lin-
comycin (Figure 3A), which induced the transcription of
bmrCD. This led to the hypothesis that particular features
within the upstream region of bmrCD could be responsible
for antibiotic-induced transcription of the two ABC trans-
porter genes. Subsequent in silico analysis of the region up-
stream of bmrC revealed a perfect intrinsic terminator-like
structure within the coding region of bmrB, together with
alternative anti-terminator and anti-anti-terminator struc-
tures as defined by the RibEx: Riboswitch Explorer algo-
rithm (18) (Figure 1B and C).
Conceivably, the terminator structure within bmrB could
play a role in the antibiotic-induced activation of the
5′bmrC-gfp construct while, as indicated above, expression
of the complete bmrBCD operon is most likely directed
from the promoter located upstream of bmrB. Expression
of the bmrCD transporter genes, however, would rely on
the decision of the RNA polymerase to either stop tran-
scription at the terminator site or continue transcription of
bmrCD. As a first approach to test this idea, the BSBII-
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Figure 3. LCA real-time analysis of bmrB transcription.A.Growth ofB. subtilisBSBII-5′bmrB-gfp (OD600 nm; gray line) and bmrB transcriptional activity
(solid black line) in response to chloramphenicol, lincomycin or erythromycin. Arrows indicate the time points at which antibiotics or an equivalent volume
of water (‘no antibiotics’) were added. Cultures entered the transition phase between exponential and post-exponential growth at OD600 of ∼1. B.Graphs
from raw GFP values as recorded with the Biotek synergy 2 plate reader. These raw values were used to calculate the TAU in panel A. Note that details
of the transcriptional activity profiles in panel A are partly obscured by background noise. C and D. Lincomycin-induced transcription of the 5′bmrC-gfp
fusion coincides with the time point at which transcription of the bmrB-gfp fusion starts to increase. Strains carrying the 5′bmrB-gfp fusion (C) or the
5′bmrC-gfp fusion (D) were grown in parallel; lincomycin was added to the BSBII-5′bmrC-gfp strain once GFP fluorescence in the BSBII-5′bmrB-gfp
strain started to increase. Note that panel C shows the raw GFP expression levels while panel D shows TAU. E. Quantitative real-time PCR analysis on
RNA isolated from B. subtilis 168 during transition-phase growth, either in the presence or absence of lincomycin (0.5 g/ml).
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5′bmrC-gfp and BSBII-5′bmrB-gfp strains were monitored
in parallel and lincomycin was added to the BSBII-5′bmrC-
gfp strain directly after the first fluorescence signal from
BSBII-5′bmrB-gfp strain was detectable (Figure 3C). The
addition of lincomycin at this point resulted in an immedi-
ate transcriptional response in the BSBII-5′bmrC-gfp strain
(Figure 3C and D). This showed that the onset of tran-
scription of bmrB coincides with the onset of antibiotic-
induced transcription of bmrCD, and it was in agreement
with our hypothesis that the putative terminator in bmrB
controls the antibiotic-induced transcription of bmrCD. To
provide additional evidence for lincomycin induction of the
bmrCD genes, we isolated RNA from B. subtilis 168 cul-
tures that were either treated with 0.5 g/ml lincomycin or
mock-treated. Real-time qPCR demonstrated that the rel-
ative expression level of bmrB was stable in these condi-
tions, whereas transcription of bmrC was increased 5- to
7-fold in lincomycin-treated cells (Figure 3E). This was in
full agreement with the data obtained from the experiments
with the promoter GFP fusions. Furthermore, we verified
that there is no alternative promoter within bmrB that con-
trols the antibiotic-induced transcription of bmrCD by re-
moving the bmrB promoter region from the 5′bmrC-gfp fu-
sion. Both the truncated and complete 5′bmrC-gfp fusions
were cloned into pRMC and were integrated into the amyE
locus. The complete 5′bmrC-gfp fusion was inducible by
lincomycin, whereas the truncated 5′bmrC-gfp fusion lack-
ing the bmrB promoter region was not inducible and dis-
played only baseline levels of GFP (Supplementary Figure
S3). Together these findings verified that transcription of the
bmrBCD operon is indeed initiated from a promoter up-
stream of bmrB. This conjoint promoter is activated dur-
ing the transition- and early-stationary growth stages and
is not responsive to ribosome-targeted antibiotics, such as
lincomycin.
The transition state regulator AbrB represses transcription of
the bmrBCD operon during exponential growth
Since expression of the bmrBCD operon was strictly re-
tained to the transition and early-stationary growth stages,
we investigated whether this could be attributed to the tran-
sition state regulator AbrB. Supporting this idea, a poten-
tial AbrB-binding site upstream of bmrB was previously
identified in a genome-wideAbrB-binding study (19). In ad-
dition, Chumsakul et al. showed that transcription of bmr-
BCD was elevated in an abrB deletion mutant, where bmrB
and bmrCD mRNA levels increased by 4- and 2-fold, re-
spectively. To verify that AbrB represses the early transcrip-
tional activation of the bmrBCD operon, we introduced
the 5′bmrC-gfp fusion into a abrB background. Indeed,
the abrB deletion resulted in derepression, precluding the
growth phase-dependent expression of the 5′bmrC-gfp fu-
sion (Figure 4, lower panel). When exponentially growing
abrB cells with the 5′bmrC-gfp fusion were subjected to
lincomycin (0.2 g/ml), this resulted in a strong expression
of GFP. However, in contrast to the abrB-proficient strain,
which displayed the reported delay, the transcriptional ac-
tivation of the 5′bmrC-gfp fusion in response to lincomycin
was considerably faster in the abrB strain (Figure 4, up-
per panel). Transcriptional activation occurred within 20
Figure 4. AbrB determines the growth phase-dependent transcription of
bmrCD. The upper panel shows the transcriptional activity (TAU) of the
5′bmrC-gfp fusion in the parental strain B. subtilis 168 (thick gray line)
and in an abrB deletion mutant (thick black line) upon lincomycin induc-
tion. The thin lines depict growth of the abrB-proficient (gray) and abrB-
deficient (black) strains carrying the 5′bmrC-gfp fusion. Lincomycin was
added to the cells during exponential growth as indicated with an arrow.
The lower panel shows the transcriptional activity (TAU) of the 5′bmrC-
gfp fusion in the parental strain 168 (thick gray line) and the abrB deletion
mutant (thick black line) grown in the absence of lincomycin. Note that the
patterns of the expression profiles for strain 168 are qualitatively similar to
those shown in Figures 2 and 3D, but that the arbitrary TAU are quan-
titatively different due to the use of plate readers with different detector
sensitivity.
min after the addition of lincomycin.We therefore conclude
that transcription of the bmrBCD operon is restrained to the
transition and early-stationary growth stages via repression
by the global transition-state regulator AbrB.
The intrinsic terminator within the bmrB-coding region con-
trols the expression of bmrCD
As demonstrated in our LCA experiments, the promoter
controlling the expression of the bmrBCD operon itself
proved to be unresponsive toward the tested antibiotics.
Therefore, we next determined whether the antibiotic-
induced expression of bmrCD could be regulated via the
putative intrinsic terminator located within the bmrB se-
quence. To test this hypothesis, we constructed two tran-
scriptional GFP fusions consisting of either a complete (1–
162 bp) or a truncated version (1–109 bp) of the bmrB-
coding sequence, the latter lacking the terminator region. In
addition, the 5′ UTR, assigned according to the B. subtilis
Expression Data Browser (17), was included in the design
(Figure 5A and Supplementary Figure S1). The two result-
ing transcriptional GFP fusions were cloned into pRM3, a
plasmid for xylose-inducible gene expression in B. subtilis.
Specifically, the resulting plasmid pRM3-bmrB162 carried
the complete bmrB sequence, while pRM3-bmrB109 car-
ried the truncated version of bmrB (Figure 5A). Strains ex-
pressing these transcriptional fusions upon induction with
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Figure 5. The 3′ end of bmrB is required for lincomycin-induced bmrCD transcription. A. Schematic representation of a part of plasmids pRM3-bmrB162
and pRM3-bmrB109. pRM3-bmrB162 was constructed by fusing the complete sequence of bmrB and its 5′-UTR to the gfp gene. pRM3-bmrB109 was
constructed by fusing a truncated version of bmrB, consisting of this gene’s first 109 nucleotides to gfp. Accordingly, pRM3-bmrB109 lacks the predicted
terminator within bmrB and part of the predicted anti-terminator. Panels B and C show the GFP fluorescence of B. subtilis carrying pRM3-bmrB162 (B)
or pRM3-bmrB109 (C) in response to xylose, lincomycin (0.75 g/ml), or a combination of xylose and lincomycin added at the time points indicated by
arrows. Xylose-induced GFP fluorescence, given in AU, was used as measure for the level of gfp expression.
0.1% xylose (final concentration; w/v) were monitored for
growth and GFP production in the presence or absence of
0.75 g/ml lincomycin.
When pRM3-bmrB162 was induced with xylose, GFP
fluorescence increased gradually to a maximum of ∼22
AU (Figure 5B). The fact that we observed expression of
GFP was an indication that the gfp gene was transcribed
and translated. In addition, this observation demonstrated
that although the bmrB terminator is present in pRM3-
bmrB162, it was not able to prevent transcription of gfp
completely. By co-induction with xylose and lincomycin,
the GFP fluorescence from pRM3-bmrB162 was more than
doubled, reaching ∼53 AU. Lincomycin alone did not in-
duce expression of GFP. This indicates that lincomycin has
no influence on transcription initiation, but rather enhances
the transcriptional elongation of bmrB.
To assess whether the bmrB terminator was involved in
the lincomycin-mediated control, we used pRM3-bmrB109.
In the strain carrying this plasmid, xylose-induced GFP
levels reached a maximum of ∼33 AU (Figure 5C), which
is a slightly higher level than that observed for the strain
carrying pRM3-bmrB162 (Figure 5B). However, by remov-
ing the terminator sequence, the lincomycin-mediated con-
trol of the xylose-induced GFP expression was completely
lost. B. subtilis pRM3-bmrB109 induced with xylose and
lincomycin, produced fluorescence levels of ∼31 AU, which
were similar to those of the xylose-induced strain with-
out lincomycin (Figure 5C). The latter shows that the re-
gion containing the bmrB terminator sequence is essential
for the lincomycin-mediated control observed for pRM3-
bmrB162. To verify the role of the terminator structure
in controlling the lincomycin-induced transcription of bm-
rCD, we constructed pRM3-bmrBTerm (Figure 6A). In
this reporter construct the formation of the terminator is
precluded, according to a RibEx: Riboswitch Explorer (18)
prediction, due to the introduction of two C to G point
mutations at positions 136 and 140 (Figure 6A and B). In
B. subtilis pRM3-bmrBTerm, the induction with xylose
alone was already sufficient to reach maximum GFP lev-
els of ∼109 AU, which corresponded to a ∼5-fold increase
compared to xylose-induced expression of the bmrB162-
gfp fusion (Figure 6C). Importantly, lincomycin-mediated
control of GFP expression was completely absent in the
strain carrying pRM3-bmrBTerm. Induction with xylose
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Figure 6. The terminator in bmrB is required for lincomycin-induced bmrCD transcription. A. Schematic representation of a part of plasmid pRM3-
bmrBTerm. Nucleotides 79–162 of the intact bmrB gene and its bmrBTerm derivative are shown; C to G point mutations at positions 136 and 140 are
marked with an asterisk (*). The predicted terminator sequence is underscored. B. Predicted structure of the terminator sequence with the position of the C
toG point mutations marked in bold and with an asterisk (*).C.MaximumGFP expression levels measured forB. subtilis strains carrying pRM3-bmrB162
(marked bmrB162) or pRM3-bmrBTerm (marked bmrBTerm) upon induction with xylose (white bars) or xylose and 0.75 g/ml lincomcyin (black
bars).
and lincomycin resulted in an average GFP level of ∼115
AU, which was comparable to that observed in the xylose-
induced cultures without lincomycin (Figure 6C). First,
these observations imply that formation of the terminator
structure is essential for lincomycin-mediated control of bm-
rCD expression. Second, the elevated GFP expression due
to the two pointmutations in the bmrBTerm-gfp fusion in-
dicates that the predicted terminator does indeed set a limit
to the expression of bmrCD. Finally, the findings presented
in Figure 6C show that lincomycin can significantly enhance
GFP expression in strains containing the bmrB162-gfp fu-
sion, but that this antibiotic cannot completely prevent the
termination event, at least at the applied lincomycin con-
centration. It thus seems that antibiotic-induced transcrip-
tion of bmrCD is at least partly controlled via the intrinsic
terminator within bmrB. Noteworthy was the observed dis-
crepancy between the GFP expression levels directed from
pRM3-bmrB109 (Figure 5C) and pRM3-bmrBTerm (Fig-
ure 6C). This observation suggests that the removal of 53 bp
of the 3′end of brmB, including the terminator plus a part
of the putative anti-terminator structure (Figures 1B and
5A), has a negative influence on the GFP expression lev-
els. In this respect, the use of point mutations, as applied in
pRM3-bmrBTerm, represents amore commendable strat-
egy.
Transcription of bmrCD is controlled via a ribosome-
mediated attenuation mechanism
With the aid of pRM3-bmrB109 and pRM3-bmrBTerm,
we demonstrated that the terminator within the coding
region of bmrB is able to regulate the expression of the
downstream bmrCD genes via a transcriptional attenuation
mechanism, which seems responsive to several ribosome-
targeted antibiotics. We therefore aimed to further charac-
terize themolecular details of this antibiotic-mediated regu-
latorymechanism. Although their precise mechanism of ac-
tion varies, all ribosome-targeted antibiotics interfere with
protein synthesis. Since bmrB contains a 53 amino acid open
reading frame (ORF), we wondered whether bmrB could
encode a potential leader peptide involved in the regulation
of transcriptional read-through via its translation.
To determine whether bmrB is translated and could thus
function as a regulatory leader peptide, we constructed a
translational BmrB-GFP fusion, using the pMUTIN-GFP
chromosomal integration plasmid (20). In this case, gfpwas
fused in-frame with the predicted bmrB-coding sequence
at the bmrB locus (Supplementary Figure S4A). However,
cells containing this construct showed no detectable GFP
fluorescence. To test whether this was due to low-level ex-
pression of BmrB-GFP from the single-copy gene fusion on
the chromosome, the in-frame bmrB-gfp fusion was PCR-
amplified and cloned in plasmid pRM3. Upon induction
with xylose, cells containing the resulting construct (pRM3-
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bmrB-gfpInframe) were fluorescent, which showed that the
bmrB open reading frame is translated and, therefore, has
the intrinsic potential to act as a regulatory leader peptide
(Supplementary Figure S4).
To test the hypothesis that bmrB could function as a
leader peptide, we constructed the transcriptional pRM3-
bmrBstart-gfp fusion in which we prevented the transla-
tion of bmrB. This was done by mutating the annotated
GTG start codon to GTC, the insertion of a TAG stop
codon downstream of the mutated start codon, and four
point mutations in the 5′-UTR that either remove alterna-
tive start codons or potential RBSs (Figure 7A). As shown
in Figure 7B, cells carrying the resulting plasmid pRM3-
bmrBstart produced ∼15 AU of GFP upon xylose induc-
tion. This was substantially lower than the GFP expression
observed for xylose-induced cells carrying pRM3-bmrB162
(Figure 7B), which suggested that impaired translation of
bmrB increases the efficiency of the transcriptional termi-
nator within the bmrB coding sequence. More importantly,
expression of the bmrBstart-gfp fusion was not inducible
with lincomycin (Figure 7B). Together, these results im-
ply that translation of bmrB is required for efficient and
lincomycin-inducible transcription of bmrCD, supporting
our hypothesis that BmrB could function as a sensory leader
peptide in a transcriptional attenuation mechanism.
In a leader peptide-based transcriptional attenuation
mechanism for bmrCD, the ribosome could conceivably
act as a sensory component for the presence of antibi-
otics which, in turn, would affect the rate of translation
of bmrB. If so, transcription downstream of the bmrB ter-
minator would depend on the effect that lincomycin ex-
erts on the ribosome. To obtain experimental evidence for
an involvement of the ribosome–lincomycin interaction in
the translation-mediated transcriptional read-through of
the bmrB terminator, we took advantage of the ermC se-
lection marker on pRM3. The encoded erythromycin ri-
bosomal methylase provides resistance to macrolides, lin-
cosamides and streptogramins by methylating a single ade-
nine residue of the 23S rRNA (the rRNA component of the
50S subunit), thereby preventing binding of the antibiotic
compound. While ermC provides cross-resistance to sev-
eral ribosome-targeted antibiotics, including lincomycin,
expression of ermC can only be induced by erythromycin
(21). To inducemethylation of the ribosomes, the strain con-
taining pRM3-bmrB162 was cultured in LB with a subin-
hibitory concentration of 0.5 g/ml erythromycin. As a
result of this, the lincomycin-mediated control on the ex-
pression of GFP was completely lost. Specifically, the in-
duction with xylose alone resulted in GFP levels similar to
those of cells grown in LB with xylose and lincomycin (∼25
AU) (Figure 7C). The fact that ribosome methylation pre-
vented the antibiotic-controlled regulation of bmrCD un-
derpins the importance of the antibiotic–ribosome interac-
tion, which is apparently required for read-through tran-
scription beyond the bmrB terminator-like sequences.
Taken together, these observations show that the
antibiotic-mediated regulation of transcriptional termi-
nation occurs during the translation of bmrB. The BmrB
peptide would then serve as a regulatory leader peptide.
In this system, the ribosomes translating the BmrB leader
peptide would act as a sensor for the presence of ribosome-
targeted antibiotics. By inhibiting protein synthesis, these
antibiotics will interfere with the efficient translation
of bmrB. In turn, this would promote the formation of
the anti-termination structure, thereby stimulating the
transcription of the downstream bmrCD genes.
Rare codons in bmrB affect the transcriptional attenuation
decision
The importance of the translation of bmrB for control-
ling the transcription of bmrCD led us to ask the ques-
tion whether the codon composition of bmrB could be
important for its function as a regulatory leader peptide.
This question was relevant since we have identified five rare
codons within the bmrB coding sequence upstream of the
regulatory terminator region (Figure 8A). The rare codons
were manually assigned based on the previously determined
codon usage inB. subtilis (22) and this was verified using the
online codon optimization tool JCat (http://www.jcat.de/)
(23). Rare codons are known to slow down the speed of
translation (24–27), and, therefore, the presence of these
rare codons within bmrB could affect the transcriptional
termination decision. To investigate this idea, a codon-
optimized bmrB sequence was designed using the JCat tool
and subsequently synthesized. This codon-optimized bmrB
sequence was transcriptionally fused to gfp and cloned
into pRM3, which resulted in plasmid pRM3-bmrBCopt
(Figure 8A). Next, the GFP expression by cells contain-
ing pRM3-bmrBCopt was compared to that of cells con-
taining pRM3-bmrB162. Interestingly, the xylose-induced
GFP expression from pRM3-bmrBCopt reached a level of
∼6.3 AU, which was much lower than the xylose-induced
GFP expression of ∼40 AU from pRM3-bmrB162 (Fig-
ure 8B). Furthermore, co-induction of the bmrBCopt-gfp
fusion with xylose and lincomycin doubled theGFP expres-
sion levels to ∼13 AU, and this 2-fold increase was com-
parable to the increase observed for the bmrB162-gfp fu-
sion induced with xylose and lincomycin, which reached
∼82 AU. Thus, although the lincomycin-mediated regula-
tion was not affected by the codon optimization, the to-
tal GFP expression levels directed from pRM3-bmrBCopt
were considerably lower compared to those directed from
pRM3-bmrB162. This suggests that the codon-optimized
bmrB sequence results in more efficient termination of the
bmrB-gfp transcript, without affecting the regulatory ca-
pacity of the terminator region. It therefore seems that the
rare codons in bmrB slow down the rate by which the cor-
responding mRNA is translated, and this might provide
sufficient time for the predicted anti-terminator to form.
In contrast, codon optimization of the bmrB sequence in-
creases the rate of translation, allowing less time for the
anti-terminator structure to form, and thereby favors tran-
scriptional termination. The latter will result in the lower
GFP levels as documented in Figure 8B. Altogether, our ob-
servations suggest that the rare codons in bmrB do not play
a major role in the lincomycin-mediated control, because
the regulatory capacity of the codon optimized bmrB se-
quence remained apparently unaffected. Instead these rare
codons seem to enhance the basal level of transcriptional
read-through. In addition, these results emphasize the im-
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Figure 7. Translation of bmrB is essential for efficient and lincomycin-induced transcription of bmrCD. A. Schematic representation of plasmid pRM3-
bmrBstart with the sequences of the first 15 nucleotides of bmrB and bmrBstart, and 70 nucleotides of the 5′-UTR. The mutations that were introduced
to preclude translation of bmrB are marked with an asterisk (*). B. Maximum GFP expression values (AU) obtained from B. subtilis carrying pRM3-
bmrB162 or pRM3-bmrBstart in response to xylose induction, either with or without lincomycin (0.75 g/ml). C. ErmC-mediated methylation of the
lincomycin-binding site on the ribosome prevents lincomycin-induced expression of bmrB-gfp. B. subtilis cells carrying pRM3-bmrB162 were pre-cultured
in medium with or without erythromycin (0.5 g/ml) and maximum GFP expression values were measured upon xylose induction, either with or without
lincomycin (0.75 g/ml). Culturing of cells in the presence of erythromycin induces expression of the ermC gene located on pRM3.
portance of the rate of translation in the regulation of read-
through transcription beyond bmrB.
DISCUSSION
In the present study, we have employed promoter-GFP fu-
sions to monitor the expression dynamics of the genes en-
coding the MDR-ABC transporter BmrCD upon expo-
sure to antibiotics. This real-time approach revealed that
the antibiotic-induced expression profile of bmrCD is con-
strained to the transition and stationary growth phases due
to a tight control by the transition state regulator AbrB.
In addition, we have demonstrated that antibiotic-induced
expression of bmrCD is regulated via a ribosome-mediated
transcription termination mechanism, a regulatory mecha-
nism that has not been previously described forMDR-ABC
transporters.
Our study shows that the promoter controlling tran-
scription of the bmrBCD operon is regulated via the tran-
scriptional regulator AbrB, which is known to repress sta-
tionary phase-specific genes during exponential growth of
B. subtilis (28), and that this regulation determines the
timing of antibiotic-induced bmrCD expression. Neverthe-
less, although the AbrB-regulated promoter upstream of
bmrB controls the growth phase-dependent expression of
bmrCD, this promoter is unresponsive to the antibiotics
that induce bmrCD expression. By constructing several dif-
ferent transcriptional-fusions, we have now demonstrated
that the antibiotic-induced expression of these two MDR-
transporter genes is regulated via the transcriptional ter-
minator located within the coding sequence of bmrB. In
the absence of antibiotics, such as lincomycin, transcrip-
tion of the bmrBCD operon will be terminated at this ter-
minator site, thereby minimizing expression of bmrCD. In
contrast, when the cells are challenged with translational
inhibitors, such as lincomycin, erythromycin or chloram-
phenicol, transcriptional termination is prevented and the
bmrCD transporter genes are transcribed. Moreover, our
study shows that translation of bmrB is essential for the
antibiotic-controlled transcription of bmrCD. From these
observations we conclude that BmrB acts as a regulatory
leader peptide, and that the extent of bmrCD transcription
is related to the efficiency of bmrB translation. Intriguingly,
kanamycin and gentamycin, both targeting the 30S riboso-
mal subunit, were unable to induce the 5′bmrC-gfp fusion,
whereas chloramphenicol, erythromycin and lincomycin,
which target the 50S subunit, did induce the 5′bmrC-gfp
fusion. This difference between antibiotics that target the
50S and 30S ribosomal subunits could relate to their exact
binding sites on the ribosome and/or mechanisms of action
in relation to bmrB translation, but this is presently highly
speculative and further research is needed to explain this
observation.
While we have identified the first leader peptide-based
transcriptional control system for the expression of an
MDR transporter, it should be noted that leader peptide-
based regulatory mechanisms have previously been re-
ported to control various other processes in bacteria. These
mechanisms rely on the fact that bacterial transcription
and translation are coupled. The best-known example of
leader peptide control involving transcriptional termination
is the operon responsible for tryptophan synthesis in E. coli
(29,30). In this case, the Trp leader peptide contains two ad-
jacent tryptophan residues involved in the sensing of tryp-
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Figure 8. Codon optimization in bmrB leads to reduced transcription of bmrCD. A. Sequences of the bmrB (marked bmrB162) and bmrBCopt genes. The
five rare codons that were mutated in bmrBCopt are marked with an asterisk (*). B. Maximum GFP expression values (AU) obtained from B. subtilis
carrying pRM3-bmrB162 or pRM3-bmrBCopt in response to xylose induction, either with or without lincomycin (0.75 g/ml).
tophan shortage, which will result in stalling of the trans-
lating ribosome at the adjacent Trp codons (31). This ribo-
some stalling promotes the formation of an anti-terminator
structure and thereby prevents premature termination of
the transcript (32). The regulation of the B. subtilis bmr-
BCD operon, as described here, differs from that of the E.
coli trp operon in that ribosome stalling is caused by the in-
hibitory effect of the ribosome-targeted antibiotics on pro-
tein synthesis instead of a tryptophan shortage. However,
as described for the trp operon, it seems likely that the ri-
bosome translational stalling will allow structural organi-
zation of the anti-terminator in bmrB, thereby promoting
the transcription of bmrCD as schematically represented in
Figure 9. In this way, the ribosome plays a regulatory role
in transcriptional regulation by acting as a sensor for com-
pounds like lincomycin that hinder efficient translation. In-
deed, our results show that the interaction between the ri-
bosome and the antibiotic is crucial for the anti-termination
process, especially since the lincomycin-induced bmrB tran-
scription was completely lost upon methylation of the ri-
bosome by ErmC (Figure 7C). The function of the pre-
dicted anti-anti-terminator (Figure 1C) within our pro-
posed transcriptional attenuationmodel remains unclear. If
functional, it is conceivable that formation of the anti-anti-
terminator structure promotes the formation of the termi-
nator, and thus, acts as an inhibiting factor for bmrCD tran-
scription.
Transcriptional termination has previously been reported
as a regulatorymechanism in the expression of several resis-
tance genes, including the B. subtilis vmlRABC transporter
gene, which is involved in resistance to lincomycin and vir-
giniamycin M (33,34). These ribosome-targeted antibiotics
also promote transcriptional read-through and thus expres-
sion of vmlR (34). However, the 5′UTR of vmlR lacks an
ORF, indicating that the expression of this gene is not reg-
ulated via ribosome-mediated transcriptional termination.
In addition, vmlR lacks the typical anti-terminator struc-
ture that is normally required for such transcriptional atten-
 at U






Nucleic Acids Research, 2014, Vol. 42, No. 18 11405
Figure 9. Model for antibiotic-induced bmrCD expression. Due to transcriptional and translational coupling, the RNA polymerase transcribing the bmrB
gene is closely followed by the respective ribosome-mRNA-BmrB nascent chain complex. A. In the absence of ribosome-targeted antibiotics, the ribosome
can translate the bmrB transcript without impediments. When bmrB is efficiently translated the formation of an anti-terminator structure, which is ener-
getically less favorable than the terminator structure (Figure 1C), is prevented. Consequently, this will result in formation of the terminator structure (T),
which will, by destabilizing the transcriptional elongation complex, result in transcriptional termination. B. The presence of antibiotics, such as lincomycin
(indicated as stars), which target the bacterial ribosome, will reduce the translation rate of bmrB. This will allow formation of the anti-terminator (AT)
structure and, thereby, preclude formation of the transcriptional terminator. In turn, this will allow the RNA polymerase to continue transcription of
bmrCD.
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uation mechanisms, and the precise mechanism regulating
vmlR expression remains to be determined (34). Further-
more, expression of ermC, encoding the erythromycin ribo-
somal methylase C, is regulated via another class of leader
peptide-based systems. Under non-inducing conditions ef-
ficient translation of the leader peptide of ermC promotes
formation of a stem-loop structure that protects the RBS so
that translation of ermC is prevented (21). The presence of
erythromycin causes stalling of the ribosome that is trans-
lating the ermC leader peptide, giving time for the forma-
tion of an alternative stem-loop structure (35). As a result,
the RBS becomes accessible, and ribosomes can efficiently
translate ermC (36). The regulatory control mechanism
of ermC encourages the theory that translational leader
peptides can act as efficient sensors for ribosome-targeted
antibiotics. This is further supported by the translation-
mediated attenuation mechanism controlling transcription
of cat-86, a plasmid-borne chloramphenicol resistance gene
in B. subtilis. Expression of cat-86 is induced when the ri-
bosome, while translating the leader peptide, is stalled by
chloramphenicol (37). Despite some overlap with the reg-
ulatory mechanisms of vmlR, ermC and cat-86, the bmrCD
genes are, to the best of our knowledge, the firstMDR-ABC
transporter genes to be regulated via ribosome-mediated
transcriptional attenuation. In fact, the termination system
controlling the expression of bmrCD is the first documented
transcriptional attenuation mechanism encoded in the B.
subtilis genome that is controlled by a leader peptide. How-
ever, it should be noted that other transcriptional attenua-
tion systems have previously been characterized in B. sub-
tilis. One example is the tryptophan synthesis operon, which
is dependent on an RNA-binding protein to control ex-
pression of downstream genes (38). Additionally, B. subtilis
has several transcriptional systems that are controlled by
riboswitches (39). These RNA elements control transcrip-
tion of downstream genes by changing their structure in
response to temperature shifts, or direct interaction with
cellular components (e.g. tRNAs) or small molecules (e.g.
amino acids, metals) (40).
The biological relevance for the observed strictly growth
phase-dependent bmrCD expression is presently elusive.
Fast and efficient detoxification of the cellular interior is es-
sential when bacteria are exposed to antibiotics. Therefore,
most drug efflux systems show an immediate transcriptional
response toward the toxic compounds they expel. However,
as a soil bacterium, B. subtilis can be confronted with a
large variety of different antimicrobial compounds and this
is probably the reason why it possesses a multitude of efflux
pumps (3). Consequently, it seems most likely that there is
overlap in the substrate specificities of the different MDR
transporters of B. subtilis. The transcriptional response of
bmrCD is strongest upon exposure to lincomycin, an antibi-
otic produced by Streptomyces lincolnensis, which is also a
soil-dwelling bacterium (41). Interestingly, the lincomcyin-
induced expression of vmlR occurs during the early- and
mid-exponential growth phases and declines in the late-
exponential growth phase (34). It thus partially overlaps
with the lincomycin-induced bmrCD expression during the
late-exponential and stationary growth stages. In addition,
lmrB, encoding an additional lincomycin exporter, follows a
similar expression profile as vmlR (42,43). Since both vmlR
and lmrB seem to be transcribed predominantly in the ex-
ponential growth phase, it appears that expression of bm-
rCD would be redundant during this point in growth and
more effective during later growth stages. An alternative ex-
planation for the strictly growth phase-dependent expres-
sion profile of bmrCD is a potential role of the respective
transporter in sporulation. Transcript levels of bmrCD in-
crease during sporulation (17), and the overexpression of
bmrCD was shown to significantly reduce spore formation
in a kinBmutantB. subtilis strain (42). Kumano et al. subse-
quently demonstrated that BmrD interacts with KinA, one
of the key regulators of the sporulation process, and they
postulated that this interaction might inhibit the activation
of KinA by trapping it to the inner surface of the cytoplas-
mic membrane.
In conclusion, the regulatory mechanism controlling the
transcription of the bmrCD genes as uncovered in the
present study points toward a role of BmrCD in antibi-
otic efflux during the post-exponential stages of growth.
This mechanism is apparently tailored for the optimal ex-
trusion of ribosome-targeted antibiotics and represents the
first ribosome-mediated transcriptional attenuation system
described for an MDR-ABC transporter.
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